Stent thrombosis in the era of drug-eluting stents [Die stentthrombose im fokus von drug-eluting stents]

被引：0

作者：

Wöhrle J. ^{[1
,2
]}

机构：

[1] Klinik für Innere Medizin II, Universitätsklinikum Ulm, Ulm

[2] Herzkathederlabore, Klinik für Innere Medizin II, Universitätsklinikum Ulm, 89081 Ulm

来源：

Herz Kardiovaskuläre Erkrankungen | 2007年 / 32卷 / 5期

关键词：

Drug-eluting stent; Myocardial infarction; Stent thrombosis;

D O I：

10.1007/s00059-007-2891-5

中图分类号：

学科分类号：

摘要：

Coronary stent thrombosis is frequently associated with death or myocardial infarction (MI). New definitions according to the Academic Research Consortium (ARC) were proposed to serve as standard criteria for stent thrombosis. According to these definitions, stent thrombosis was classified as acute (within 24 h post implantation), subacute (1-30 days), late (31 days to 1 year), and very late (later than 1 year). Furthermore, stent thrombosis was differentiated in definite with angiographic or autoptic verification, probable, and possible. In meta-analyses using the ARC criteria, the occurrence of subacute stent thrombosis did not differ between drug-eluting stents (DES; Cypher, Taxus) or bare-metal stents (BMS) with < 1%. Very late stent thrombosis occurred 0.4-0.6% more frequently with DES compared to BMS. Available follow-up periods are limited to 4 years. The occurrence of death and MI did not differ between DES and BMS within the total follow-up period. In the meta-analysis of the Taxus studies, the event rates (death and MI) were initially lower with DES compared to BMS based on the reduced need for target vessel revascularization. Nevertheless, this was compensated in the following period by a higher event rate due to very late stent thrombosis. In real-world registries, the event rates are higher than in the first randomized studies. With DES implantation as a routine strategy, the occurrence of angiographically documented stent thrombosis was 2.9% within a period of 3 years. Classic predictors for stent thrombosis with BMS remain relevant also in the DES era. The delayed endothelialization with DES in combination with suboptimally implanted DES takes the patients to a higher and longer risk for stent thrombosis. Several guidelines recommend dual antiplatelet therapy for 12 months after DES implantation in noncomplex lesions. In complex lesions combined antiplatelet treatment should be prescribed 24 months or longer (e.g., DES after brachytherapy). Patients scheduled for surgical procedures or patients with reduced compliance should not be treated with DES. © 2007 Urban & Vogel.

引用

页码：411 / 418

页数：7

共 56 条

[1]

Cutlip D.E., Baim D.S., Ho K.K., Et al., Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials, Circulation, 103, pp. 1967-1971, (2001)

[2]

Malenka D.J., O'Rourke D., Miller M.A., Et al., Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty, Am Heart J, 137, pp. 632-638, (1999)

[3]

Iakovou I., Schmidt T., Bonizzoni E., Et al., Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents, JAMA, 293, pp. 2126-2130, (2005)

[4]

Kuchulakanti P.K., Chu W.W., Torguson R., Et al., Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents, Circulation, 113, pp. 1108-1113, (2006)

[5]

Schuhlen H., Kastrati A., Dirschinger J., Et al., Intracoronary stenting and risk for major adverse cardiac events during the first month, Circulation, 98, pp. 104-111, (1998)

[6]

Uren N.G., Schwarzacher S.P., Metz J.A., Et al., Predictors and outcomes of stent thrombosis. An intravascular ultrasound registry, Eur Heart J, 23, pp. 124-132, (2002)

[7]

Cheneau E., Leborgne L., Mintz G.S., Et al., Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study, Circulation, 108, pp. 43-47, (2003)

[8]

Brodie B.R., Cooper C., Jones M., Et al., Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT trial, Cathet Cardiovasc Interv, 59, pp. 184-192, (2003)

[9]

Fujii K., Carlier S.G., Mintz G.S., Et al., Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study, J Am Coll Cardiol, 45, pp. 995-998, (2005)

[10]

Wenaweser P., Dorffler-Melly J., Imboden K., Et al., Stent thrombosis is associated with an impaired response to antiplatelet therapy, J Am Coll Cardiol, 45, pp. 1748-1752, (2005)

← 1 2 3 4 5 6 →